October 28, 2019
(NASDAQ: DARE) – A clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes […]
October 28, 2019
A designer and developer of sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine, whose lead drug product candidate utilizes patent protected sustained-release drug-delivery technology designed to meet the specific and unique needs […]
October 11, 2019
A privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the synapse, the building blocks of brain health and function. […]